ORMP News Oramed Pharmaceuticals Chosen to Pres
Post# of 144503
ORMP News
Oramed Pharmaceuticals Chosen to Present at the XVI International Symposium on Atherosclerosis (ISA2012), (March 25-29, 2012; Sydney, Australia)
2012-03-20 09:20 ET - News Release
Company Website: http://www.oramed.com
JERUSALEM -- (Business Wire)
Oramed Pharmaceuticals Inc. (OTCBB: ORMP) ( www.oramed.com ), a developer of oral drug delivery systems, announced today that its work entitled "Decreased CRP levels in response to a six-week, once-daily oral insulin regimen" will be presented at the XVI International Symposium on Atherosclerosis (ISA2012) on March 25-29, 2012, to be held in Sydney, Australia.
"The selection of Oramed as one of the companies to present at the ISA2012 is a great opportunity for us to apprise the scientific community of the important progress we have made," said Dr. Miriam Kidron, Oramed's Chief Scientific Officer.
Oramed's poster will be presented on March 26, 2012, during poster session #1.
For more information about the conference, please visit www.isa2012.com .
For more information about Oramed Pharmaceuticals, please visit www.oramed.com .
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule, currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.
(0)
(0)